$PRLD News

Last published 3w ago

3w agoPRLDCHARDAN HEALTHCARE CONFERENCE - PRELUDE THERAPEUTICS INCEarnings Call TranscriptsOkay, awesome. Let's do our next session. We have Prelude Therapeutics. My name is Gautam Chukar. I'm a biotech analyst here at Shorin Capital. And on stage with me, we have Brian Lim, CFO of Prelude Therapeutic and Pegg
3w agoPRLDPrelude Therapeutics to Participate in the Chardan Healthcare ConferenceGlobeNewswireWILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the
4w agoPRLDPrelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast CancerGlobeNewswireCombination cohorts are part of Prelude’s Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026 The collaboration is underpinned by
2mo agoPRLDPrelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective DegraderGlobeNewswireWILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company
3mo agoPRLDPrelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireThe Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating differentiated
5mo agoPRLDJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - PRELUDE THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, everyone. Thank you for joining us today here in our Jeffries Healthcare Conference in New York. I have the pleasure today, joined by Chris Vardy and Peggy Shrill of Prelude Therapeutics. Why don't we go
6mo agoPRLDPrelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireInitiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class
6mo agoPRLDPrelude Therapeutics Announces Pricing of $90.0 Million Underwritten OfferingGlobeNewswireWILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the pricing of its
6mo agoPRLDPrelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026GlobeNewswireData Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer Prelude Remains on Track to File
7mo agoPRLDPrelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical OfficerGlobeNewswireWILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude Therapeutics" or the "Company"), a clinical-stage precision oncology company, today announced that Dr.
8mo agoPRLDPrelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026GlobeNewswireReceived FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and
9mo agoAUTL IMNM MRNA ONCY+1The $71 Billion Cancer Shift: Why The FDA Is Speeding UpGlobeNewswireVANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and
9mo agoPRLDPrelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F InhibitorGlobeNewswireWILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to
11mo agoCNTX IMNM ONCY PRLD+1Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval StandardsGlobeNewswireVANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster
11mo agoPRLDPrelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) ProgramsGlobeNewswireFirst disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in
11mo agoALXO ERAS IMRX ONCY+1Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106BGlobeNewswirePALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies
12mo agoPRLDPRELUDE THERAPEUTICS THIRD QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL - PRELUDE THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone, and welcome, everyone to the Prelude Therapeutics Investor Conference call. Today's call is being recorded and is expected to last up to 45 minutes. At this time, I will now turn the call over to
12mo agoPRLDPrelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireLead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing
1y agoPRLDPrelude Therapeutics Announces Strategic Business UpdateGlobeNewswirePrelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement
1y agoINCY PRLDPrelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 InhibitorsGlobeNewswireIncyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with
1y agoPRLDPrelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual MeetingGlobeNewswireWILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of two
1y agoPRLDPrelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of DirectorsGlobeNewswireWILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of
1y agoPRLDPrelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by
1y agoPRLDPrelude Therapeutics to Participate in Upcoming Healthcare ConferencesGlobeNewswireWILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two
1y agoPRLDPrelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily,
1y agoPRLDPrelude Therapeutics to Participate in Citizens Life Sciences ConferenceGlobeNewswireWILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the
1y agoPRLDPrelude Announces Presentations at 2025 AACR Annual MeetingGlobeNewswirePreclinical data elucidating the mechanism of action of PRT3789, Prelude's first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude's efforts to discover and
1y agoPRLDPrelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025GlobeNewswirePRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with SMARCA4-deficient, non-small cell lung (NSCLC), gastric and
1y agoPRLDPrelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare ConferenceGlobeNewswireWILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the
1y agoPRLDPrelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid MalignanciesGlobeNewswire• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy • Prelude plans to seek a partner for future development of PRT2527
1y agoPRLDPrelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology SummitGlobeNewswireWILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the
2y agoPRLDPrelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswirePresented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept Initiated a Phase 1 trial for PRT7732, its first-in-class
2y agoPRLDPrelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR SymposiumGlobeNewswire– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) – First safety data presented from combination study of PRT3789 and
2y agoPRLDPrelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR SymposiumGlobeNewswireWILMINGTON, Del., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of three
2y agoPRLDPrelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 TrialGlobeNewswire- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation
2y agoPRLDPrelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024GlobeNewswirePRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST) Prelude will host an
2y agoPRLDPrelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireInterim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September Received
2y agoPRLDPrelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated CancersGlobeNewswireCombining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two mechanisms. Prelude
2y agoPRLDPrelude Therapeutics to Participate in Upcoming Healthcare ConferencesGlobeNewswireWILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming
2y agoPRLDPrelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceGlobeNewswireWILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the
2y agoPRLDPrelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireFirst-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included
2y agoPRLDPrelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingGlobeNewswireHighly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527,
2y agoPRLDPrelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingGlobeNewswireWILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the
2y agoPRLDPrelude Therapeutics to Participate in Barclays Global Healthcare ConferenceGlobeNewswireWILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the
2y agoPRLDPrelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024GlobeNewswireFirst-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in
2y agoPRLDPrelude Therapeutics Announces $25 Million Private PlacementGlobeNewswireWILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced a private placement that
3y agoPRLDPrelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsGlobeNewswirePrioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio of precision ADCs
3y agoABCL PRLDPrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyBusiness WireMulti-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader Prelude Therapeutics Incorporated
3y agoABCL PRLDPrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyGlobeNewswireWILMINGTON, Del. & VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD) and AbCellera (NASDAQ:ABCL) today announced a multi-year, multi-program
3y agoPRLDPrelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International ConferenceGlobeNewswireWILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical